AGLE Annual Cash & Cash Equivalents
$34.86 M
+$19.72 M+130.24%
31 December 2022
Summary:
As of January 29, 2025, AGLE annual cash & cash equivalents is $34.86 million, with the most recent change of +$19.72 million (+130.24%) on December 31, 2022. During the last 3 years, it has risen by +$15.61 million (+81.08%).AGLE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AGLE Quarterly Cash And Cash Equivalents
$90.59 M
-$144.77 M-61.51%
30 September 2023
Summary:
As of January 29, 2025, AGLE quarterly cash and cash equivalents is $90.59 million, with the most recent change of -$144.77 million (-61.51%) on September 30, 2023. Over the past year, it has increased by +$51.60 million (+132.35%).AGLE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AGLE Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +130.2% | +132.3% |
| 3 y3 years | +81.1% | +67.1% |
| 5 y5 years | +172.0% | +523.4% |
AGLE Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | ||||
| 5 y | 5-year | ||||
| alltime | all time | -61.3% | -61.5% |
Aeglea BioTherapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2023 | - | $90.59 M(-61.5%) |
| June 2023 | - | $235.36 M(+567.8%) |
| Mar 2023 | - | $35.24 M(+1.1%) |
| Dec 2022 | $34.86 M(+130.2%) | $34.86 M(-10.6%) |
| Sept 2022 | - | $38.99 M(+4.1%) |
| June 2022 | - | $37.47 M(+156.0%) |
| Mar 2022 | - | $14.64 M(-3.3%) |
| Dec 2021 | $15.14 M(-83.2%) | $15.14 M(-38.6%) |
| Sept 2021 | - | $24.66 M(-29.1%) |
| June 2021 | - | $34.77 M(-56.7%) |
| Mar 2021 | - | $80.23 M(-10.9%) |
| Dec 2020 | $90.09 M(+368.0%) | $90.09 M(+66.2%) |
| Sept 2020 | - | $54.22 M(-17.5%) |
| June 2020 | - | $65.71 M(+421.8%) |
| Mar 2020 | - | $12.59 M(-34.6%) |
| Dec 2019 | $19.25 M | $19.25 M(-21.6%) |
| Sept 2019 | - | $24.55 M(-3.5%) |
| June 2019 | - | $25.43 M(-70.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $85.64 M(+281.3%) |
| Dec 2018 | $22.46 M(+75.2%) | $22.46 M(+54.6%) |
| Sept 2018 | - | $14.53 M(-29.4%) |
| June 2018 | - | $20.58 M(+91.3%) |
| Mar 2018 | - | $10.76 M(-16.0%) |
| Dec 2017 | $12.82 M(-73.2%) | $12.82 M(-2.6%) |
| Sept 2017 | - | $13.16 M(-51.1%) |
| June 2017 | - | $26.93 M(+60.3%) |
| Mar 2017 | - | $16.80 M(-64.8%) |
| Dec 2016 | $47.75 M(+63.0%) | $47.75 M(-3.6%) |
| Sept 2016 | - | $49.54 M(-29.9%) |
| June 2016 | - | $70.63 M(+194.1%) |
| Mar 2016 | - | $24.02 M(-18.0%) |
| Dec 2015 | $29.29 M(+1019.8%) | $29.29 M(-5.0%) |
| Sept 2015 | - | $30.84 M(-21.1%) |
| June 2015 | - | $39.08 M(-10.8%) |
| Mar 2015 | - | $43.79 M(+1574.0%) |
| Dec 2014 | $2.62 M(-43.1%) | $2.62 M |
| Dec 2013 | $4.60 M | - |
FAQ
- What is Aeglea BioTherapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Aeglea BioTherapeutics?
- What is Aeglea BioTherapeutics annual cash & cash equivalents year-on-year change?
- What is Aeglea BioTherapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Aeglea BioTherapeutics?
- What is Aeglea BioTherapeutics quarterly cash and cash equivalents year-on-year change?
What is Aeglea BioTherapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AGLE is $34.86 M
What is the all time high annual cash & cash equivalents for Aeglea BioTherapeutics?
Aeglea BioTherapeutics all-time high annual cash & cash equivalents is $90.09 M
What is Aeglea BioTherapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AGLE annual cash & cash equivalents has changed by +$19.72 M (+130.24%)
What is Aeglea BioTherapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AGLE is $90.59 M
What is the all time high quarterly cash and cash equivalents for Aeglea BioTherapeutics?
Aeglea BioTherapeutics all-time high quarterly cash and cash equivalents is $235.36 M
What is Aeglea BioTherapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, AGLE quarterly cash and cash equivalents has changed by +$51.60 M (+132.35%)